Demographic and clinical characteristics at initiation of RFX treatment
| Demographic and clinical characteristics (n=138 unless specified otherwise) | |
| Female (n, %) | 53 (38%) |
| Age, years (mean (±SD)) | |
| At diagnosis of cirrhosis | 58.2 (12.1) |
| At diagnosis of HE | 60.2 (11.7) |
| At initiation of RFX | 60.9 (11.6) |
| Phenotype (n, %) | |
| Overt | 109 (79%) |
| Covert | 29 (21%) |
| Time from cirrhosis diagnosis to initiation of RFX, months | |
| Mean (SD), n=133 | 32.3 (36.5) |
| Median (IQR), n=133 | 21.1 (6.7–47.2) |
| Time from HE diagnosis to initiation of RFX, months | |
| Mean (SD) | 9.0 (17.6) |
| Median (IQR) | 3.1 (0.4–10.5) |
| Underlying liver disease aetiology (not mutually exclusive, n (%)) | |
| Alcohol-related liver disease | 96 (70%) |
| Non-alcoholic steatohepatitis | 32 (23%) |
| Hepatitis B or C | 14 (10%) |
| Autoimmune hepatitis | 2 (1%) |
| Non-alcoholic fatty liver disease | 2 (1%) |
| Cryptogenic | 4 (3%) |
| Other | 3 (2%) |
| On liver transplant list at initiation (n, %) | |
| Yes | 6 (4%) |
| No | 132 (96%) |
| Proportion of patients with prior TIPSS at initiation of RFX (n, % n=131) | |
| Yes procedural | 21 (16%) |
| No | 110 (84%) |
| Not recorded | 7 |
| Child-Pugh score (n, % n=55) | |
| A | 4 (7%) |
| B | 32 (58%) |
| C | 19 (35%) |
| Not recorded | 83 |
| MELD score (n, % n=100) | |
| <10 | 12 (12%) |
| 10<15 | 37 (37%) |
| 15<20 | 19 (19%) |
| 20<25 | 11 (11%) |
| 25 or higher | 21 (21%) |
| Not recorded | 38 |
| ALBI score (n, % n=127) | |
| ≤−2.60 (grade 1) | 12 (9%) |
| >−2.60 to ≤ −1.39 (grade 2) | 63 (50%) |
| >−1.39 (grade 3) | 52 (41%) |
| Not recorded | 11 |
| Alcohol use status (n, % n=117) | |
| Currently drinking alcohol | 23 (20%) |
| Not currently drinking alcohol | 94 (80%) |
| Not recorded | 21 |
ALBI, albumin-bilirubin; HE, hepatic encephalopathy; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; RFX, rifaximin; TIPSS, transjugular intrahepatic portosystemic shunt.